Kornimate/medical-research-clean huggingface dataset:
effects of pulmonary rehabilitation on respiratory sounds in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the effect of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (copd) has been based on systemic outcome measures, however, little is known about the effectiveness of this intervention on patients' lung function. the forced expiratory volume in one second (fev1), despite of being the gold standard for assessing lung function in copd, is poorly responsive to pulmonary rehabilitation. thus, an objective and responsive outcome measure to assess the effect of pulmonary rehabilitation on lung function is needed. computerized respiratory sounds have been found to be a more sensitive indicator, detecting and characterizing the severity of respiratory diseases before any other measure, however its potential to detect changes after pulmonary rehabilitation has never been explored. therefore, this study aims to assess the effects of pulmonary rehabilitation on the characteristics of computerized respiratory sounds in patients with copd. a randomized controlled study with one group undergoing pulmonary rehabilitation (n=25) and other group receiving standard care (n=25) will be conducted. the pulmonary rehabilitation program will included exercise training (3\*week) and psychoeducation (1\*week). computerized respiratory sounds, lung function, exercise capacity, quadriceps muscle strength, health-related quality of life and health services use will be assessed in both groups, at baseline, immediately post-intervention and at follow-ups (3 and 6 months after pr). descriptive and inferential statistics will be used. it is expected that significant changes occur on the characteristics of computerized respiratory sounds in patients enrolled in the pulmonary rehabilitation group, in comparison with patients receiving standard care. thus, computerized respiratory sounds could provide a simple, objective and non-invasive measure to assess lung function changes after pulmonary rehabilitation.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd according to the global initiative for chronic obstructive lung disease (gold) criteria; * ≥ 18 years old; * clinical stability for 1 month prior to the study (no hospital admissions, exacerbations or changes in medication); * able to provide their own informed consent. exclusion criteria: * presence of concomitant respiratory diseases; * presence of severe psychiatric conditions; * presence of severe neurologic/ musculoskeletal conditions and/or unstable cardiovascular disease.

Keywords: chronic obstructive pulmonary disease (copd) pulmonary rehabilitation computerized respiratory sounds
perfluorocarbon liquid vs. posterior retinotomy during pars-plana vitrectomy for rhegmatogenous retinal detachment

Conditions: Rhegmatogenous Retinal Detachment

Summary: purpose to evaluate the outcomes of perfluorocarbon liquid (pfcl) versus posterior retinotomy (pr) during pars plana vitrectomy (ppv) for rhegmatogenous retinal detachment (rrd), focusing on anatomical success, visual acuity, intraocular pressure (iop), and complications. methods this is a prospective randomized controlled trial that included 58 eyes with rrd, divided into group a (pfcl, n = 29) and group b (pr, n = 29). preoperative assessments included best-corrected visual acuity (bcva), iop, axial length, lens status, macula status, and pvr grade. outcomes were evaluated at 1 week, 1 month, 2 months, and 3 months postoperatively. primary outcomes included retinal reattachment rates and the number of operations; secondary outcomes included bcva, iop changes, complications like cataract development, retinal redetachment, epiretinal membrane (erm) formation, and single-surgery success.


Eligibility criteria:
inclusion criteria: a clear diagnosis of primary rrd requiring surgery, 18 years or older, the potential to return for follow-up visits for at least 6 months post-surgery. exclusion criteria: when presented with tractional or exudative retinal detachment, had surgery on the affected eye in the past, presented with severe eye disorders like advanced glaucoma or endophthalmitis.
europainclinics® study v (prospective observational study)

Conditions: Back Pain; Intervertebral Disc Herniation

Summary: in this prospective observational trial the effect of the endoscopic discectomy microinvasive therapy should be examined in (approximately 500) adult patients with low back pain.


Eligibility criteria:
inclusion criteria: * lumbar disc prolapse with unilateral radiculopathy, on clinical evaluation, positive straight leg raise or femoral stretch test, and identification of a single nerve root lesion on mri exclusion criteria: * the exlusion criteria: bilateral root symptoms, double root involvement, cauda equina syndrome and negative mri picture for disc herniation, unsigned infomed consent
different treatment options for tubal ectopic pregnancy:- a systmatic review

Conditions: Woman With Tubal Ectopic Pregnancy

Summary: ectopic pregnancy is an early pregnancy complication in which a fertilized ovum implant outside the uterine cavity. implantation may occur anywhere along the reproductive tract with the most common implantation site being the fallopian tube. the incidence of ectopic pregnancy is 1% of pregnant women, and may seriously compromise women's health and future fertility. currently, ectopic pregnancy can be often diagnosed before the woman's condition has deteriorated, which has altered the former clinical picture of a lifethreatening disease into a more benign condition in frequently asymptomatic women.


Eligibility criteria:
inclusion criteria: * rcts and observational studies * all types of ectopic pregnancies. * all types of treatments and medications for ectopic pregnancies. * the long-term survival of patients with or without complications. * successful pregnancy and birth. exclusion criteria: * articles of failed treatments of ectopic pregnancies. * articles with over all p value \> 0.05. * articles for which the full text is not available in english.
yttrium y-90 radioembolization in treating patients with metastatic liver cancer

Conditions: Metastatic Liver Carcinoma; Stage IV Liver Cancer; Stage IVA Liver Cancer; Stage IVB Liver Cancer

Summary: this clinical trial studies the side effects and best way to perform yttrium y-90 radioembolization in treating patients with liver cancer that has spread to other places in the body (metastatic). yttrium y-90 radioembolization is a therapy that injects radioactive microspheres directly into an artery that feeds liver tumors to cut off their blood supply. performing yttrium y-90 radioembolization in a single session may make treatment faster, minimize patient travel, and decrease the overall cost of the procedure.

primary objective: i. to evaluate the feasibility and safety of same day yttrium-90 radioembolization planning and treatment angiography. secondary objectives: i. to determine the patient costs associated with same diagnostic and treatment compared when compared to the standard two session methodology. ii. to determine the time required to perform the mandatory in-room technetium tc-99m albumin aggregated (99mtc-maa) imaging and the associated calculations for the lung shunt fraction and treatment 90y-microsphere activity. iii. to determine the time for delivery of the therapy 90y-microsphere radioactivity to the angiography suite after the therapy written directive by the authorized user. outline: the first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. during the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. during the second visit, patients undergo a second angiography and receive yttrium y 90 resin microspheres via arterial microcatheter. patients then undergo single-photon emission computed tomography-computed tomography (spect-ct) bremsstrahlung imaging. all subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours. after completion of study treatment, patients are followed up at 1, 3, and 6 months.

Eligibility criteria:
inclusion criteria: * the ability to understand and sign informed consent * any candidate eligible for standard of care y90 radioembolization for treatment of their primary or metastatic liver tumors exclusion criteria: * patients with greater than 50% liver tumor burden
vitamin d status fluctuations over one academic year in students

Conditions: Vitamin D Deficiency

Summary: the main objective of the study is to assess changes in the concentration of vitamin d metabolite in serum throughout the academic year and to examine its relationship with the occurrence of inflammation indicators, dietary habits, nutritional status, severity of depressive states, and cognitive abilities in a group of students. an additional objective will be to assess the relationship between the genotype in the cyp2r1 gene and the concentration of 25(oh) vitamin d.


Eligibility criteria:
inclusion criteria: * no chronic diseases * student status * age 18-30 years exclusion criteria: * chronic diseases (related to malabsorption, kidney and liver diseases) * not active student status * age \ 30 years
a trial of the c-trac intervention for dementia patients

Conditions: Dementia

Summary: the goal of the project is to conduct a prospective, randomized-controlled clinical trial to determine the extent to which the coordinated-transitional care (c-trac) program impacts transitional care quality, patient cognition/function, caregiver stress and 30-day rehospitalizations in patients with documented diagnoses of dementia discharged from the hospital to the community.

patients with dementia often experience poor quality transitions from the hospital to the community. in response, the investigators developed and piloted the coordinated-transitional care (c-trac) program--a low-cost, telephone-based intervention designed to improve care coordination and outcomes in hospitalized patients with dementia or other high-risk conditions discharged to community settings. a single-blind, prospective, randomized-controlled trial will be used with participants being randomly assigned to receive usual (i.e. standard) care, or usual care plus the c-trac intervention. outcomes will be assessed via scheduled phone-calls at 14, 30, and 90 days post-hospitalization. a 45-day phone call will also be conducted to complete a brief satisfaction survey with the caregiver about their post-hospital experience.

Eligibility criteria:
patient inclusion criteria: * english-speaking * have a working telephone * hospitalized on medical inpatient wards at uwhc * a documented pre-hospitalization diagnosis of dementia. * alzheimer's disease cooperative study - clinical dementia rating (adcs-cdr) score of \> 0 * have a family member/informal caregiver who has regular contact with them in the community setting caregiver inclusion criteria: * english-speaking * have a working telephone * have contact with patient a minimum of once per week patient exclusion criteria: * discharged to institutional settings * no identified caregiver * discharged to hospice * followed by complex case management or any form of intensive case management (e.g. transplant, congestive heart failure, dialysis) * score moderate-high on modified assist tool for alcohol

Keywords: dementia transitional care caregiver
ovature (ovarian tumor response) a phase iii study of weekly carboplatin with and without phenoxodiol in patients with platinum-resistant, recurrent epithelial ovarian cancer

Conditions: Fallopian Tube Cancer; Peritoneal Neoplasms; Ovarian Cancer

Summary: the purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may result.


Eligibility criteria:
inclusion criteria: * histologically-confirmed ovarian, fallopian, or primary peritoneal carcinoma of epithelial origin * recurrent or persistent advanced disease * have measurable disease * undergone at least two courses of therapy with a platinum drug (cisplatin or carboplatin) and have responded to the first of those courses of therapy as determined by either response evaluation criteria in solid tumors (recist) or gynecologic cancer intergroup (gcig) criteria * disease relapse as determined by either recist or gcig criteria within 6 months of completion of the second or greater course of platinum therapy using a 2-, 3- or 4-weekly regimen and platinum-free interval of no greater than 6 months at the time of enrollment, being the time taken from the last day of platinum therapy * any number of previous courses of platinum therapy or non-platinum therapy * likely to survive at least 3 months * karnofsky performance score of at least 60% * have adequate physiological function without evidence of major organ dysfunction as evidenced by: * serum creatinine \< 1.5 mg/dl * serum transaminase levels ≤ 3 x the upper limit of normal (uln) for the reference laboratory and * bilirubin level \< uln * have adequate hematological function defined by: * platelets \> 100,000/mm3 * white cell counts (wcc) \> 3,000/mm3 * neutrophils \> 1,500/mm3 * hemoglobin \> 8.0 g/dl * aged \> 18 * be able to understand the risks and benefits of the study and give written informed consent to participation. exclusion criteria: * patients with mucinous histological type of ovarian cancer * patients who have failed to show a clinical response (recist or gcig criteria) to at least one prior course of platinum therapy * patients with active infection * patients with concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, hypertension, ischemic heart disease, congestive heart failure, etc.) * patients with a history of chronic active hepatitis or cirrhosis * patients with hiv * patients with active central nervous system (cns) metastases. patients with known cns metastases must have received prior radiation therapy, and cns metastatic disease must be stable for 4 weeks. * patients who have not recovered from the acute effects of any prior anti-neoplastic therapy * patients with known hypersensitivity to platinum drugs that cannot be managed with concomitant medication.

Keywords: recurrent ovarian epithelial cancer stage iv ovarian epithelial cancer peritoneal cavity cancer stage iii ovarian epithelial cancer
shuntcheck-micro-pumper pediatric clinical outcomes study

Conditions: Suspected CSF Shunt Obstruction

Summary: primary objective is to demonstrate that data collected from shuntcheck-micro-pumper (scmp) testing results can be used in conjunction with imaging to diagnose shunt patency or obstruction in pediatric/adolescent subjects presenting to an emergency department or neurosurgery clinic (ed/nc). scmp results and scmp results combined with other diagnostic methods, including the attending physician's and the neurosurgeon's clinical judgment will be compared to clinical outcomes within 7 days of ed/nc visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.


Eligibility criteria:
inclusion criteria: 1. males or females, older than 35 months and less than 20 years of age. 2. parent/guardian or alert subject (age 18 or over) capable of giving consent; subject less than 18 and of assent age must give assent to participate if appropriate and required by the institution. if the subjects are incapable of giving assent, then only parent/guardian consent is required. 3. possess an unambiguously identifiable chronically indwelling ventricular shunt which crosses the clavicle. 4. suspicion of shunt obstruction is great enough to warrant the performance of any diagnostic test for this condition 5. will be available for follow-up for up to 7 days exclusion criteria: 1. inability or unwillingness of the parent/guardian or alert subject to give informed consent/assent (when appropriate) as required by the institutional review board. 2. presence of multiple shunts or known non-functioning shunts crossing the clavicle. 3. evaluating staff rule out shunt obstruction on the basis of a physical/clinical examination. 4. scmp test would interfere with emergent subject care or if the subject is scheduled to go the or in short order. 5. presence of an interfering open wound or edema over the shunt. 6. likelihood, in the judgment of the investigator, of the subject being lost to follow-up as a result of subject unavailability or clinical outcome being unobtainable. 7. any other condition that would preclude or bias the results of the study according to the judgment of the investigator. 8. judgment of the investigator that participation in the study will interfere with, or be detrimental to, administration of optimal health-care to the subject.

Keywords: hydrocephalus csf shunt shunt malfunction shunt obstruction shuntcheck shuntcheck-micro-pumper
combined effects of sensory integration and vestibular exercises on post-stroke patients

Conditions: Post Stroke

Summary: the aim of this study is to determine the combined effects of sensory integration and vestibular exercise on dizziness, fall risk and quality of life.

this randomized controlled trial will be conducted at mansoorah teaching hospital in 7 months after the approval of the synopsis. 38 participants with stroke will be included as per the sample size calculation through the convenience sampling technique. participants who meet inclusion criteria will be randomly allocated using an online randomization tool into two groups group a will receive combine sensory integration exercise and vestibular exercise with routine physical therapy for 40 minutes and group b will receive vestibular exercise with routine physical therapy for 40 minutes. each group will receive a treatment session of 3 times in week for 6 weeks. the data will be analyzed using spss version 24.

Eligibility criteria:
inclusion criteria: * both male and female * age between 40years-65years * those who have been diagnosed with vestibular disorders * an ability to stand for for 5 minutes without aid measured by 5 times sit to stand test. exclusion criteria: * have bilateral or unstable vestibular loss * any neurological condition is present * active bppv is present * any acute orthopaedic condition is present * peripheral neuropathy is present * visual impairment not corrected with glasses.

Keywords: sensory integration, stroke vestibular rehabilitation
longitudinal morphometric changes following sci

Conditions: Spinal Cord Injury

Summary: in patients with chronic spinal cord injury, imaging of the spinal cord and brain above the level of the lesion provides evidence of neural degeneration; however, the spatial and temporal patterns of progression and their relation to clinical outcomes are uncertain. new interventions targeting acute spinal cord injury have entered clinical trials but neuroimaging outcomes as responsive markers of treatment have yet to be established. we aim to use mri to assess neuronal degeneration above and below the level of the lesion after acute spinal cord injury. in our prospective longitudinal study, we enroll patients with acute traumatic spinal cord injury and healthy controls. we assess patients clinically and by mri at baseline, 2 months, 6 months, 12 months, and if possible 24 months and 60 months follow-up, and controls by mri at the same timepoints. we assess cervical atrophy in white and gray matter and use cross-sectional spinal cord area measurements to assess atrophy at cervical level (c2/c3) and in the lumbar enlargement. we use myelinsensitive magnetisation transfer (mt) and longitudinal relaxation rate (r1) maps in the brain to assess microstructural changes associated with myelin. we also use diffusion tensor imaging acquired in the spinal cord at c2/c3 and in the lumbar enlargement to identify axonal loss and demyelination in the spinal white matter. finally, we assess associations between mri parameters and clinical improvement.


Eligibility criteria:
inclusion criteria: sci patients: * acute injury to the spinal cord * no medical or mental illness * written informed consent * over the age of 18 years control subjects: * over the age of 18 years * written informed consent exclusion criteria: sci patients: * head or brain lesion associated with the trauma leading to the injury * epileptic seizures * mri contraindications * pregnant women or lactating women control subjects: * pregnant women or lactating women * mri contraindications * neurological or psychiatric illness
subjective observational study of patients using transdermal cream medication and/or transdermal patches with or without oral non-narcotic medications

Conditions: Pain, Chronic; Pain, Joint; Pain Syndrome

Summary: purpose of this study is to evaluate the level of pain perceived by patients using a transdermal cream and/or transdermal patch with or without an oral medication as a pain management solution.

the purpose of this minimal risk, observational study is to observe and document patients' perspective on how the combination of transdermal cream and/or transdermal patch(s) with or without oral medication can help reduce or eliminate the use of opiate(s).

Eligibility criteria:
inclusion criteria: * participants must be diagnosed with an icd10 code indicative of chronic pain * participants must be starting a new regimen of topical therapy with or without non-narcotic oral medication that has been deemed medically necessary and is independent of the study * participants must be expecting to receive therapy for at least 12 weeks * participants must be between 18 and 64 years of age * participants must be able to provide sound verbal informed consent exclusion criteria: * participants must not be a beneficiary of government funded healthcare program (i.e. medicare, medicaid, etc.) * participants must not have a diagnosis of cancer within the past 5 years * participants who have chronic pain conditions not expected to respond to topical pain medication such as deep abdominal pain, or from conditions such as cancer